Clinical Trial Update: LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated LBH589 (panobinostat) alone or with erythropoietin-stimulating agents in low- or Int-1 risk myelodysplastic syndromes; the study was t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• LBH589 (panobinostat) (panobinostat)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Myelodysplastic Syndrome (MDS) | Phase 2 | Status: TERMINATED | Results posted: 2017-01-25